PO:07:095 | Clinical impact of therapeutic modification following changes in AIFA reimbursement criteria for JAK inhibitors in patients with RA in remission/low disease activity: analysis of the multicenter JAK-SWAP RER study in Emilia-Romagna
Background. Since March 2023, AIFA has introduced new reimbursement criteria for JAK-inhibitors (JAKis), restricting their use to patients with rheumatoid arthritis (RA) without specific risk factors and with previous failure of bDMARD therapy. These restrictions have influenced prescribing behavio...
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
PAGEPress Publications
2025-11-01
|
| Collection: | Reumatismo |
| Sujets: | |
| Accès en ligne: | https://www.reumatismo.org/reuma/article/view/2135 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|